第五届疫苗中国发展国际峰会顺利闭幕

cao1976

随着国家免疫规划的持续扩容及政府对生物产业的大力扶持，中国疫苗市场增长快速并在过去几年成为全球增长最快的市场。 预计至2015年，中国疫苗市场将超过200亿元。通过广泛的合作，包括EV71，s-IPV疫苗在内的多个重要一秒相继研发成功并即将生产上市。此外，随着治疗性疫苗国际工程实验室的正式启动，中国将迎来一波治疗性疫苗的开发热潮。在中生成都所获得WHO首个预认证后，包括华兰生物、科兴生物等一批国内疫苗企业的产品也相继进入WHO预认证后期审查。中国企业正在以前所未有的热情，提升生产工艺及质量管理体系，以期成为国际市场的合格竞争者。

在人用疫苗迅速发展的同时，兽用疫苗产业在最近几年同样迎来了黄金发展期。国际强制免疫规划促使市场扩容，而国内传染性疾病的频繁爆发及国际绿色壁垒，促使规模日益壮大的养殖业对疫苗的需求大增。尤其是市场苗，已成为行业的主要增长点。预计2016年，中国动物疫苗市场将超过150亿元，并且保持年均24%的高速增长。市场方面，国内新生产线投资呈现爆发式增长，外资企业同样加快了进军中国市场的步伐，或新建生产基地，或通过与本土企业在研发、销售等领域建立广泛合作。新型疫苗的开发、抗原浓缩纯化及悬浮细胞培养技术成为行业关注的热点。

借此热潮，第五届疫苗中国发展国际峰会（VacChina 2015）今日在沪开幕，作为2015年中国最大的疫苗行业年会，大会通过人用疫苗及兽用疫苗两个分论坛分别探讨行业的最新发展趋势，研发战略，合作模式，生产技术等热点话题。同时也与政府权威机构共同探讨国际免疫规划、疫苗审批注册等方面的最新政策动向。
大会开幕，由北京民海生物总经理、大会主席郑海发做开幕致辞，随后中牧股份副董事长胡启毅结合当前热门的互联网时代下，中国动物疫苗产业的演进。值得关注的是，北京民海生物总经理郑海发、厦门万泰CEO高永忠、上海巴斯德研究所疫苗中心执行主任金侠、上海润泽生物CEO史力、Panacea BiotecCEORajinder Kumar Suri起就各自领域和视角一起讨论未来疫苗发展的趋势。
上海润泽生物CEO史力发言表示疫苗创新缓慢的原因主要是由于疫苗作用于健康人群，任何一个国家的药监局对于疫苗的管控都是最严格的，为保证疫苗的稳定性，药监部门对于疫苗开发中任何创新的东西都会亮红灯。因此许多基金会包括比尔盖茨等都极其支持开发稳定的疫苗。上海巴斯德研究所疫苗中心执行主任金侠建议，建立疫苗的临床评价平台非常重要，对促进行业的健康发展起着重要的作用。
与会嘉宾们希望通过本次大会的讨论，促进国内外疫苗企业及其它相关机构在市场拓展、研发及生产等方面的区域性合作，从而推动疫苗产业的健康、快速发展。



转自生物探索网http://www.biodiscover.com/news/activity/117905.html

cao1976

Key Issues
Human Vaccine Forum:

·         China and global vaccine overview: supply and demand  

·         Strategies for expanding vaccine capabilities in China

·         Integrating Chinese vaccine into global Market

·         Dengue/HIV/Malaria /Flu/therapeutic vaccine development update

·         Advances in Technologies for purification and large-scale manufacturing

·         Managing quality throughout the whole bioprocess

·         Development of Cell-culture based vaccine

·         Vaccine delivery system and technologies

·         Adjuvant/Formulation technologies

·         Best practice for GMP, QA/QC, WHO Pre qualification Review




Animal Vaccine Forum:


·         Strategies to development veterinary vaccine in China

·         Catching big opportunities in global animal vaccine market through novel strategic partnership model

·         Regulatory Requirements for Conventional and Next Generation Veterinary Vaccines

·         Suspension culture and microcarrier culture techniques applied in animal vaccine manufacturing

·         Novel adjuvant technology in vaccine development

·         Recombined vaccine development

·         Aquatic/pet/poultry/ PCV II/FMDV vaccine development

·         Cross Sector Collaboration and Commercialization

cao1976

大会主席简介：


Mr. Haifa Zheng established Beijing Minhai Biotechnology Co., Ltd as the General Manager in June 2004.

He began his career in 1990 with Beijing Veterinarian Experimentation Clinic. In 1993, he served as the research associate and team leader of Rabies Vaccine Team for National Pharmaceutical & Biological Products Control Institute. During 1996 to 1998, he joined the National University of Singapore as research scholar on Rabies Vaccine Program.

He returned to government service in 1998 as associate research and team leader of Rabies Vaccine Team for National Pharmaceutical & Biological Products Control Institute. In 2003, he served as the section chief of Department of Biological Products and Chief Scientist of SARS Vaccine Program for National Commission of New Drug Development Foundation.

Mr. Haifa Zheng served as the adjunct professor for Third Military Medical University, as the member of committee of experts for China Health Care Association, as the member of Standing Committee of Daxing District Committee for CPPCC, as the Vice Director of P3 Class Lab. and Researcher for Beijing Entry-Exit Inspection & Quarantine Bureau, and as the GMP inspector for SFDA.

From June 2004, Mr. Haifa Zheng joined Beijing Minhai Biotechnology Co., Ltd as the General Manager, and the Vice General Manager as Shenzhen Kangtai Biological Products Co., Ltd. is in charging for the daily operation management for Minhai.

marine0425030

老大，多谢分享。。